Literature DB >> 20624125

Cripto-1: an embryonic gene that promotes tumorigenesis.

Nadia Pereira de Castro1, Maria Cristina Rangel, Tadahiro Nagaoka, David S Salomon, Caterina Bianco.   

Abstract

Several studies have shown that cell fate regulation during embryonic development and oncogenic transformation share common regulatory mechanisms and signaling pathways. Indeed, an embryonic gene member of the EGF-Cripto-1/FRL1/Cryptic family, Cripto-1, has been implicated in embryogenesis and in carcinogenesis. Cripto-1 together with the TGF-beta ligand Nodal is a key regulator of embryonic development and is a marker of undifferentiated human and mouse embryonic stem cells. While Cripto-1 expression is very low in normal adult tissues, Cripto-1 is re-expressed at high levels in several different human tumors, modulating cancer cell proliferation, migration, epithelial-to-mesenchymal transition and stimulating tumor angiogenesis. Therefore, inhibition of Cripto-1 expression using blocking antibodies or antisense expression vectors might be a useful modality not only to target fully differentiated cancer cells but also to target a subpopulation of tumor cells with stem-like characteristics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624125     DOI: 10.2217/fon.10.68

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  24 in total

Review 1.  Targeting the embryonic gene Cripto-1 in cancer and beyond.

Authors:  Caterina Bianco; David S Salomon
Journal:  Expert Opin Ther Pat       Date:  2010-11-13       Impact factor: 6.674

Review 2.  The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition.

Authors:  Malgorzata Klauzinska; Nadia P Castro; Maria Cristina Rangel; Benjamin T Spike; Peter C Gray; Daniel Bertolette; Frank Cuttitta; David Salomon
Journal:  Semin Cancer Biol       Date:  2014-08-19       Impact factor: 15.707

3.  Cripto-1 enhances the canonical Wnt/β-catenin signaling pathway by binding to LRP5 and LRP6 co-receptors.

Authors:  Tadahiro Nagaoka; Hideaki Karasawa; Thomas Turbyville; Maria-Cristina Rangel; Nadia P Castro; Monica Gonzales; Alyson Baker; Masaharu Seno; Stephen Lockett; Yoshimi E Greer; Jeffrey S Rubin; David S Salomon; Caterina Bianco
Journal:  Cell Signal       Date:  2012-09-27       Impact factor: 4.315

4.  Common structural traits for cystine knot domain of the TGFβ superfamily of proteins and three-fingered ectodomain of their cellular receptors.

Authors:  A Galat
Journal:  Cell Mol Life Sci       Date:  2011-03-03       Impact factor: 9.261

Review 5.  Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer.

Authors:  Maria C Rangel; Hideaki Karasawa; Nadia P Castro; Tadahiro Nagaoka; David S Salomon; Caterina Bianco
Journal:  Am J Pathol       Date:  2012-04-26       Impact factor: 4.307

6.  Cripto-1 expression and its prognostic value in human bladder cancer patients.

Authors:  Bingbing Wei; Wei Jin; Jun Ruan; Zhuoqun Xu; You Zhou; Jiabei Liang; Huan Cheng; Ke Jin; Xing Huang; Peng Lu; Qiang Hu
Journal:  Tumour Biol       Date:  2014-10-19

7.  Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells.

Authors:  Caterina Bianco; Nadia P Castro; Christina Baraty; Kelly Rollman; Natalie Held; Maria Cristina Rangel; Hideaki Karasawa; Monica Gonzales; Luigi Strizzi; David S Salomon
Journal:  J Cell Physiol       Date:  2013-06       Impact factor: 6.384

8.  Repression of Zeb1 and hypoxia cause sequential mesenchymal-to-epithelial transition and induction of aid, Oct4, and Dnmt1, leading to immortalization and multipotential reprogramming of fibroblasts in spheres.

Authors:  Yongqing Liu; Partha Mukhopadhyay; M Michele Pisano; Xiaoqin Lu; Li Huang; Qingxian Lu; Douglas C Dean
Journal:  Stem Cells       Date:  2013-07       Impact factor: 6.277

9.  Cripto-1 Promotes the Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma Cells.

Authors:  Chun Huang; Wangsheng Chen; Xiaowen Wang; Jinqiu Zhao; Qian Li; Zhongxue Fu
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-17       Impact factor: 2.629

10.  Cripto-1 as a novel therapeutic target for triple negative breast cancer.

Authors:  Nadia P Castro; Natalie D Fedorova-Abrams; Anand S Merchant; Maria Cristina Rangel; Tadahiro Nagaoka; Hideaki Karasawa; Malgorzata Klauzinska; Stephen M Hewitt; Kajal Biswas; Shyam K Sharan; David S Salomon
Journal:  Oncotarget       Date:  2015-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.